AU4840199A - Thyroid hormone analogues and methods for their preparation - Google Patents

Thyroid hormone analogues and methods for their preparation Download PDF

Info

Publication number
AU4840199A
AU4840199A AU48401/99A AU4840199A AU4840199A AU 4840199 A AU4840199 A AU 4840199A AU 48401/99 A AU48401/99 A AU 48401/99A AU 4840199 A AU4840199 A AU 4840199A AU 4840199 A AU4840199 A AU 4840199A
Authority
AU
Australia
Prior art keywords
compound
hydrogen
alkyl
formula
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU48401/99A
Other languages
English (en)
Inventor
Grazia Chiellini
Timothy J. Mitchison
Thomas S. Scanlan
Hikari A. I. Yoshihara
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
University of California Berkeley
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California, University of California Berkeley filed Critical University of California
Publication of AU4840199A publication Critical patent/AU4840199A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C321/00—Thiols, sulfides, hydropolysulfides or polysulfides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
    • C07C69/708—Ethers
    • C07C69/712—Ethers the hydroxy group of the ester being etherified with a hydroxy compound having the hydroxy group bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C323/11—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/16—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • C07C59/70—Ethers of hydroxy-acetic acid, e.g. substitutes on the ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU48401/99A 1998-06-30 1999-06-28 Thyroid hormone analogues and methods for their preparation Abandoned AU4840199A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9118598P 1998-06-30 1998-06-30
US60091185 1998-06-30
PCT/US1999/014627 WO2000000468A1 (en) 1998-06-30 1999-06-28 Thyroid hormone analogues and methods for their preparation

Publications (1)

Publication Number Publication Date
AU4840199A true AU4840199A (en) 2000-01-17

Family

ID=22226506

Family Applications (1)

Application Number Title Priority Date Filing Date
AU48401/99A Abandoned AU4840199A (en) 1998-06-30 1999-06-28 Thyroid hormone analogues and methods for their preparation

Country Status (13)

Country Link
US (1) US6107517A (enExample)
EP (2) EP1598334A1 (enExample)
JP (1) JP2002519340A (enExample)
KR (1) KR20010053277A (enExample)
AT (1) ATE293595T1 (enExample)
AU (1) AU4840199A (enExample)
CA (1) CA2335551C (enExample)
DE (1) DE69924846T2 (enExample)
DK (1) DK1089968T3 (enExample)
ES (1) ES2241294T3 (enExample)
IL (1) IL140140A0 (enExample)
PT (1) PT1089968E (enExample)
WO (1) WO2000000468A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5883294A (en) * 1997-06-18 1999-03-16 The Regeants Of The University Of California Selective thyroid hormone analogs
CA2374266A1 (en) * 1999-06-01 2000-12-07 The University Of Texas Southwestern Medical Center Method of treating hair loss using diphenylmethane derivatives
MXPA01012494A (es) 1999-06-01 2002-07-02 Univ Texas Southwestern Med Ct Metodo para tratar perdida capilar con el uso de compuestos sulfonil tiromimeticos.
US6723717B1 (en) 1999-06-01 2004-04-20 The University Of Texas Southwestern Medical Center Sulfur-containing thyroxane derivatives and their use as hair growth promotors
US6680344B1 (en) 1999-06-01 2004-01-20 The University Of Texas Southwestern Medical Center Method of treating hair loss using diphenylmethane derivatives
US20040132830A1 (en) * 2001-01-19 2004-07-08 Finer Jeffrey T Triphenylmethane kinesin inhibitors
US7302347B2 (en) * 2002-12-10 2007-11-27 The Regents Of The University Of California Method for creating specific, high affinity nuclear receptor pharmaceuticals
SE526033C3 (sv) * 2003-11-06 2009-12-08 Metso Paper Inc Silanordning och silkorg för silning av massasuspensioner
EP2428516A1 (en) 2003-11-19 2012-03-14 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
US20090232879A1 (en) 2005-05-26 2009-09-17 Metabasis Therapeutics, Inc. Thyromimetics for the Treatment of Fatty Liver Diseases
RU2007148927A (ru) * 2005-05-26 2009-07-10 Метабэйзис Терапьютикс, Инк. (Us) Новые тиреомиметики, содержащие фосфиновую кислоту
WO2007002036A1 (en) * 2005-06-24 2007-01-04 Thomas Lavin Tyroid hormone in burn and adipose deposites
WO2014178892A1 (en) 2013-05-03 2014-11-06 Scanlan Thomas S Use of sobetirome in the treatment of x-linked adrenolenoleukodystrophy
MX382313B (es) * 2016-05-18 2025-03-13 Univ Oregon Health & Science Derivados del sobetiroma.
WO2018094265A2 (en) 2016-11-21 2018-05-24 Viking Therapeutics, Inc. Method of treating glycogen storage disease
AU2018280118B2 (en) 2017-06-05 2021-07-15 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis
EA202091979A1 (ru) 2018-03-22 2021-06-22 Вайкинг Терапьютикс, Инк. Кристаллические формы и способы получения кристаллических форм соединения
EP4775207A2 (en) 2018-12-05 2026-07-15 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis
EP3894383A1 (en) 2018-12-12 2021-10-20 Autobahn Therapeutics, Inc. Novel thyromimetics
CA3130371A1 (en) 2019-03-01 2020-09-10 Autobahn Therapeutics, Inc. Novel thyromimetics
CN115279359A (zh) 2019-11-29 2022-11-01 速通医疗公司 新型拟甲状腺素药
EP4161925A4 (en) 2020-06-09 2024-09-04 Viking Therapeutics, Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIVER DISEASES
EP4168384A4 (en) 2020-06-17 2024-07-10 Autobahn Therapeutics, Inc. THYROMIMETICS
EP4167986A4 (en) 2020-06-17 2024-11-20 Autobahn Therapeutics, Inc. THYROMIMETICS
AU2022271304A1 (en) 2021-05-06 2023-11-23 Autobahn Therapeutics, Inc. Fatty acid amide hydrolase (faah) cleavable prodrugs of thyromimetics and combination with peripherally restricted faah inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3332957A (en) * 1964-09-02 1967-07-25 Ciba Geigy Corp Amino esters of substituted phenoxy acetic acids
JPS5195049A (en) * 1975-02-12 1976-08-20 * **********so*****no***tsu*****************************************ni*no
US4323691A (en) * 1979-10-09 1982-04-06 Abbott Laboratories Hydroxyaminomethyl derivatives of benzoyl di-substituted α-phenoxyalkanoyl esters
US5883294A (en) * 1997-06-18 1999-03-16 The Regeants Of The University Of California Selective thyroid hormone analogs

Also Published As

Publication number Publication date
KR20010053277A (ko) 2001-06-25
US6107517A (en) 2000-08-22
ES2241294T3 (es) 2005-10-16
ATE293595T1 (de) 2005-05-15
WO2000000468A1 (en) 2000-01-06
DE69924846D1 (de) 2005-05-25
CA2335551C (en) 2009-03-03
CA2335551A1 (en) 2000-01-06
DE69924846T2 (de) 2006-04-27
DK1089968T3 (da) 2005-08-22
IL140140A0 (en) 2002-02-10
EP1089968A4 (en) 2002-08-21
EP1089968A1 (en) 2001-04-11
EP1089968B1 (en) 2005-04-20
PT1089968E (pt) 2005-08-31
EP1598334A1 (en) 2005-11-23
JP2002519340A (ja) 2002-07-02

Similar Documents

Publication Publication Date Title
EP1089968B1 (en) Thyroid hormone analogues and methods for their preparation
EP0991618B1 (en) Selective thyroid hormone analogs
US7750048B2 (en) GPR40 agonists
JP2002519340A5 (enExample)
CN101835737A (zh) 螺环化合物及其药学用途
PL171403B1 (pl) Sposób wytwarzania nowych 20-metylo-podstawionych pochodnych witaminy D PL PL
JPH09165369A (ja) 1α,26−ジヒドロキシ−D−ホモ−ビタミンD3
FR2787789A1 (fr) Benzopyranes et benzoxepines utilisables dans le traitement de dyslipidemies, de l'atherosclerose et du diabete, compositions pharmaceutiques les contenant et procedes de preparations
CN111757770B (zh) 作为gpr40激动剂的3-苯基-4-己炔酸衍生物
EP1692127B1 (en) Triphenylethylene compounds as selective estrogen receptor modulators
US6822120B2 (en) Sulfone liver X-receptor modulators
HU215448B (hu) Eljárás kinoncsoportot tartalmazó tiazolidinszármazékok előállítására
EP1742902B1 (en) Hexenoic acid derivatives, processes for the preparation thereof, pharmaceutical compositions comprising them, and therapeutic applications thereof
LU86404A1 (fr) Ethers cyclopentyliques,leur procede de preparation et compositions pharmaceutiques
AU2003294861B2 (en) Indenoncarboxylic acids derivatives and their use for the treatment of and preventing diabetes and dyslipidaemia
WO1997035835A1 (en) 3,4-disubstituted phenylethanolaminotetralincarboxylate derivatives
CA2050514A1 (en) Acyclic tocotrienol analogs in the treatment of hypercholesterolemia and hyperlipidemia
EP0571928A1 (en) Acyclic Tocotrienol analogs in the treatment of hypercholesterolemia and hyperlipidemia
CN118829630A (zh) 一种多环类甲状腺激素β受体激动剂及其用途
US20080015253A1 (en) Pentenoic Acid Derivatives, Processes For The Preparation Thereof, Pharmaceutical Compositions Comprising Them, And Therapeutic Applications Thereof
JP2005500402A (ja) 1α,25−ジヒドロキシビタミンD3の24−硫黄置換類縁体
EP1546083B1 (en) Novel substituted arylhexadienoic acids and esters thereof which can be used for the treatment and prevention of diabetes, dyslipidaemia and atherosclerosis, pharmaceutical compositions comprising them and processes for the preparation of them
JP2008512384A (ja) Pparアゴニスト活性を有するフィブラート化合物
AU2004263254B2 (en) Butenoic acid derivatives, processes for the preparation thereof, pharmaceutical compositions comprising them, and use for the treatment of dyslipidaemia, atherosclerosis and diabetes
EP0345457B1 (en) Antinflammatory agent for the therapy of prostatic hypertrophy, a process for the preparation thereof and pharmaceutical compositions containing it

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted